

Inhibitors of the Oncogenic Transcription Factor AP-1 from *Podocarpus latifolius*

Krishna P. Devkota,[†] Ranjala Ratnayake,^{†,‡} Nancy H. Colburn,[§] Jennifer A. Wilson,[†] Curtis J. Henrich,^{†,⊥} James B. McMahon,[†] and John A. Beutler^{*,†}


[†]Molecular Targets Laboratory, Molecular Discovery Program, National Cancer Institute, Frederick, Maryland 21702, United States

[§]Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States

[⊥]SAIC-Frederick, Inc., Frederick, Maryland 21702, United States

S Supporting Information

ABSTRACT: An activator protein-1 (AP-1) based bioassay-guided phytochemical investigation on *Podocarpus latifolius* led to the isolation of three new sempervirent-type diterpenes, cycloinmakiol (1), inumakal (2), and inumakoic acid (3), along with three known norditerpenes (4–6). Compounds 4 and 6 were responsible for the observed bioactivity.




Carcinogenesis, the process of transforming normal cells into cancer cells, is a multistage process of initiation, promotion, and progression. The activator protein-1 (AP-1), an oncogenic transcription factor, is a heterodimeric or homodimeric protein complex that is required for tumor promotion and progression.^{1,2} The heterodimer AP-1 consists of Jun (c-Jun, Jun B, and Jun D) paired with Fos (c-Fos, Fos B, Fra 1, and Fra 2) proteins; homodimers of Jun proteins also exist.³ The N-terminally truncated c-Jun (TAM67) mutant protein has been shown to form homodimers or heterodimers with other Jun or Fos family members, which bind to AP-1 sequences, that subsequently demonstrate no or diminished AP-1 transactivation.⁴ It has been shown that molecules that mimic TAM67 in inhibiting 12-O-tetradecanoyl phorbol-13-acetate (TPA)-stimulated AP-1 activity may be valuable for the prevention and treatment of cancers.^{1,2} Hence, a search for novel and specific AP-1 inhibitors from natural products, including those of plant origin, might be beneficial for the prevention and therapy of cancer. We recently developed a high-throughput assay to screen natural product extracts for such inhibitors.² An organic solvent extract of the root bark of *Podocarpus latifolius* (Thunb.) R.Br. ex Mirb. collected in Tanzania demonstrated activity in this assay and was subjected to bioassay-guided fractionation.

Podocarpus is one of the most widely distributed genera of the family Podocarpaceae, with about 100 species having diverse morphology, ecology, and chemical constituents. A number of medicinal and nonmedicinal ethnobotanical uses are reported for the genus *Podocarpus*.⁵ Different biological activities such as cytotoxic, antibacterial, anti-inflammatory, antioxidant, and tyrosinase inhibitory properties have been reported for compounds from *Podocarpus*.^{5–11}

P. latifolius is a slow-growing evergreen tree that can reach a height of 30 m. The norditerpene dilactone macrophyllin acid and several biflavones have previously been reported from

P. latifolius.¹² Our bioassay-guided phytochemical investigation with respect to AP-1 led to the isolation of three new (1–3) and three known (4–6) diterpenes.



RESULTS AND DISCUSSION

The fractionation of root bark extract (CH₂Cl₂–MeOH) of *P. latifolius* by successive diol and LH-20 column chromatography

Special Issue: Special Issue in Honor of Koji Nakanishi

Received: October 14, 2010

Published: February 09, 2011

Compound **2** was isolated as a reddish gum. The IR spectrum of **2** exhibited absorptions at 3549, 1714, and 1550 cm^{-1} for phenolic hydroxy, carbonyl, and aromatic bonds, respectively.¹³ The molecular formula of **2** was determined to be $\text{C}_{20}\text{H}_{29}\text{O}_2$ in HREIMS ($[\text{M} + \text{H}]^+$ at m/z 301.2172, calcd 301.2162), corresponding to the presence of seven degrees of unsaturation. The analysis of 1D and 2D NMR data of compound **2** showed distinct similarities to compound **1** with major differences at C-20 and C-19. The C-20 methyl protons resonated as a 3H singlet at δ_{H} 1.03 with a carbon shift value of δ_{C} 24.4, whereas the formyl proton of C-19 appeared as a singlet at δ_{H} 9.80 with a carbon shift of δ_{C} 206.1. The ^1H and ^{13}C NMR data of compound **2** are presented in Table 1. Hence, compound **2** was concluded to be 11-hydroxy-14-isopropyl-8,11,13-podocarpatrien-19-al and was named inumakal.

Compound **3** was isolated as a reddish gum. The IR spectrum of **3** exhibited absorptions at 3053, 1734, and 1550 cm^{-1} for carboxylic acid hydroxy, carbonyl, and aromatic bonds, respectively.¹³ The molecular composition of **3** was found to be $\text{C}_{20}\text{H}_{29}\text{O}_3$ by HREIMS ($[\text{M} + \text{H}]^+$ at m/z 317.2112, calcd 317.2111), corresponding to seven degrees of unsaturation. The 1D and 2D NMR data of compound **3** showed many similarities to compound **2** except for the presence of a carboxylic acid instead of a formyl group at C-4. The acid carbonyl resonated at δ_{C} 183.2. The ^1H and ^{13}C NMR data of compound **3** are presented in Table 1. Hence, compound **3** was concluded to be 11-hydroxy-14-isopropyl-8,11,13-podocarpatrien-19-oic acid and was named inumakoic acid.

Together with these three new semperviol diterpenes, three known norditerpenes, **4**–**6**, were isolated and identified on the basis of a comparison of their spectroscopic data with the literature. The known norditerpenes were identified as nagilactone F (**4**), inumakilactone B (**5**), and inumakilactone (**6**).^{6,14–16} The ^{13}C NMR data of compound **6** have not been previously published and thus are shown in Table 1. The originally proposed stereostructures of **5** and **6** have been revised by others as shown and are consistent with our data.⁶

All six compounds were evaluated for their ability to inhibit phorbol ester TPA-induced activation of AP-1 activity. Only compounds **4** and **6** had significant activity at the concentrations tested, with IC_{50} values estimated from dose–response curves of 1.5 and 4.0 μM , respectively. However, both of these compounds also appeared to be toxic, with cell survival of <50% in each case at more than 2.5 μM .

EXPERIMENTAL SECTION

General Experimental Procedures. Optical rotations were measured on a Perkin-Elmer 241 polarimeter in a 100 \times 2 mm cell (units 10^{-1} deg $\text{cm}^2 \text{g}^{-1}$). UV absorption spectra were obtained using a Varian Cary 50 Bio UV–visible spectrophotometer. IR spectra were measured using a JASCO FT/IR-6100 type A spectrometer. LCMS were obtained using a Hewlett-Packard Series 1100 MSD, whereas HRMS were acquired on an Agilent 6520 Accurate Mass Q-TOF instrument with internal reference masses at 121.05087 and 922.00979, both within 5 ppm. The NMR experiments were performed on a Bruker 600 MHz NMR spectrometer. ^1H and ^{13}C spectra were referenced to deuterated solvent peaks. The diol DIO Spe-ed SPE cartridge was used for fractionation of the extract, whereas Sephadex LH-20 columns attached to a model UA-6 UV detector and Foxy 200 fraction collector (Teledyne Isco) were used for further fractionation and purification of the compounds. All solvents and chemicals were of analytical grade.

Plant Material. The root bark of *Podocarpus latifolius* (Thunb.) R. Br. ex Mirb. (517.0 g dry weight, Q66T0357, N017773) was collected on October 8, 1988, by Roy Gereau and James Lovett of the Missouri Botanical Garden at Luisenga Stream, Mufundi District, Iringa Province, Tanzania (1710 m elevation) and identified by James Lovett. A voucher specimen was deposited in the Missouri Botanical Garden herbarium as R. Gereau & J. Lovett 2635.

Extraction and Isolation. The dried root bark of *P. latifolius* was ground and extracted with CH_2Cl_2 –MeOH (1:1 v/v) by the standard NCI method to yield 66.25 g of organic extract.¹⁷ Part (101.4 mg) of this extract was used for the AP-1-based bioassay-guided extraction and isolation of compounds. The extract was loaded on a diol DIO Speed SPE cartridge and eluted with 6.0 mL each of hexanes– CH_2Cl_2 (9:1), CH_2Cl_2 –EtOAc (20:1), EtOAc, and EtOAc–MeOH (5:1) to give four fractions, A–D, of 4.3, 22.5, 16.0, and 53.0 mg, respectively. The AP-1 activity of fraction B was found to be higher than the other fractions and was selected for further fractionation and isolation of compounds. Fraction B (21.0 mg) was chromatographed on a 1.5 \times 40 cm Sephadex LH-20 column and eluted with hexanes– CH_2Cl_2 –MeOH (2.5:1, v/v), with 150 drop fractions collected in each tube. On the basis of the UV-absorption (254 nm), eight fractions, A1–H1, were collected. The fractions A1–H1 were between the tubes 1–11, 12–19, 20–26, 27–32, 33–36, 37–44, 45–55, and 56–66, respectively. Among the eight fractions, fraction A1–D1, F1, and G1 were found to be pure and correspond to compounds **5** (2.1 mg), **4** (6.6 mg), **6** (2.8 mg), **2** (3.6 mg), **1** (2.5 mg), and **3** (2.9 mg), respectively.

Cycloinumakiol (**1**): reddish gum (CHCl_3); $[\alpha]_{\text{D}}^{25} +49$ (c 0.015, MeOH); UV (MeOH) λ_{max} (log ϵ) 280.0 (4.21), 226.5 (3.71) nm; IR (KBr) ν_{max} 1601, 1547 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 1; HR-EIMS $[\text{M} + \text{H}]^+$ m/z 285.2222 (calcd for $\text{C}_{20}\text{H}_{29}\text{O}$ 285.2212).

Inumakal (**2**): reddish gum (CHCl_3); $[\alpha]_{\text{D}}^{25} +20$ (c 0.021, MeOH); UV (MeOH) λ_{max} (log ϵ) 280.0 (4.43), 226.5 (3.89) nm; IR (KBr) ν_{max} 3549, 1714, 1550 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 1; HR-EIMS $[\text{M} + \text{H}]^+$ m/z 301.2172 (calcd for $\text{C}_{20}\text{H}_{29}\text{O}_2$ 301.2162).

Inumakoic acid (**3**): reddish gum (CHCl_3); $[\alpha]_{\text{D}}^{25} +13$ (c 0.018, MeOH); UV (MeOH) λ_{max} (log ϵ) 280.0 (4.43), 226.5 (3.62) nm; IR (KBr) ν_{max} 3053, 1734, 1550 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 1; HR-EIMS $[\text{M} + \text{H}]^+$ m/z 317.2112 (calcd for $\text{C}_{20}\text{H}_{28}\text{O}_3$ 317.2111).

AP-1 Assay. The ability of compounds and fractions to inhibit TPA-induced AP-1 activation was assessed as described.² Briefly, cells expressing β -lactamase under the control of the AP-1 promoter were treated for 18 h with tetradecanoyl phorbol acetate (TPA) in the presence or absence of putative inhibitors. Activity was normalized to that of cells treated with TPA only. Cytotoxicity was evaluated by estimating effects of compounds on cell numbers by a separate XTT assay. Samples were added in DMSO solution in triplicate.

ASSOCIATED CONTENT

Supporting Information. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*Tel: 301-846-1942. Fax: 301-846-6177. E-mail: beutlerj@mail.nih.gov.

Present Addresses

[†]Department of Medicinal Chemistry, University of Florida, Health Science Center, P5-27, P.O. Box 100485, Gainesville, FL 32610

ACKNOWLEDGMENT

We thank T. McCloud, SAIC-Frederick, Inc., Frederick, MD, and the Natural Products Support Group for plant grinding and

extraction, the CCR Biophysics Resource for providing technical assistance with HR-EIMS measurements, and K. Gustafson, Molecular Targets Laboratory, National Cancer Institute, Frederick, MD, for helpful comments. This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported [in part] by the Intramural Research Program of NIH, National Cancer Institute, Center for Cancer Research.

■ DEDICATION

Dedicated to Dr. Koji Nakanishi of Columbia University for his pioneering work on bioactive natural products.

■ REFERENCES

- (1) Young, M. R.; Li, J. J.; Rincón, M.; Flavell, R. A.; Sathyanarayana, B. K.; Hunziker, R.; Colburn, N. *Proc. Natl. Acad. Sci. U. S. A.* **1999**, *96*, 9827–9832.
- (2) Ruocco, K. M.; Goncharova, E. I.; Young, M. R.; Colburn, N. H.; McMahon, J. B.; Henrich, C. J. *J. Biomol. Screen.* **2007**, *12*, 133–139.
- (3) Angel, P.; Karin, M. *Biochim. Biophys. Acta* **1991**, *1072*, 129–157.
- (4) Brown, P. H.; Alani, R.; Prei, L. H.; Szabo, E.; Birrer, M. J. *Oncogene* **1993**, *8*, 877–886.
- (5) Abdillahi, H. S.; Stafford, G. I.; Finnie, J. F.; Van Staden, J. S. *Afr. J. Bot.* **2010**, *76*, 1–24.
- (6) Sato, K.; Inaba, Y.; Park, H.-S.; Akiyama, T.; Koyama, T.; Fukaya, H.; Aoyagi, Y.; Takeya, K. *Chem. Pharm. Bull.* **2009**, *57*, 668–679.
- (7) Park, H.-S.; Kai, N.; Fukaya, H.; Aoyagi, Y.; Takeya, K. *Heterocycles* **2004**, *63*, 347–357.
- (8) Kuo, Y.-J.; Hwang, S.-Y.; Wu, M.-D.; Liao, C.-C.; Liang, Y.-H.; Kuo, Y.-H.; Ho, H.-O. *Chem. Pharm. Bull.* **2008**, *56*, 585–588.
- (9) Reynolds, M.; Chaturvedula, V. S. P.; Ratovosons, F.; Andriant-siferana, R.; Rasamison, V. E.; Guza, R. C.; Kingston, D. G. I. *Nat. Prod. Res.* **2006**, *20*, 606–610.
- (10) Sato, K.; Sugawara, K.; Takeuchi, H.; Park, H.-S.; Akiyama, T.; Koyama, T.; Aoyagi, Y.; Takeya, K.; Tsugane, T.; Shimura, S. *Chem. Pharm. Bull.* **2008**, *56*, 1691–1697.
- (11) Abdillahi, H. S.; Finnie, J. F.; Van Staden, J. *J. Ethnopharmacol.* **2011**, in press.
- (12) Fozdar, B. I.; Khan, S. A.; Shamsuddin, K. M. *J. Indian Chem. Soc.* **1989**, *66*, 423–424.
- (13) Pavia, D. L.; Lampman, G. M.; Kriz, G. S. *Introduction to Spectroscopy*, 2nd ed.; Harcourt Brace College Publishers: USA, 1996.
- (14) Hayashi, Y.; Yokoi, J.; Watanabe, Y.; Sakan, T. *Chem. Lett.* **1972**, 759–762.
- (15) Hayashi, Y.; Matsumoto, T.; Uemura, M. *Org. Magn. Reson.* **1980**, *14*, 86–91.
- (16) Hori, M. *Steroids* **1969**, *14*, 33–46.
- (17) McCloud, T. G. *Molecules* **2010**, *15*, 4526–4563.